ghk cu injectable safety adverse events GHK-Cu Peptide FDA scientists flag concerns with

Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP1 and amylin analogues owenhaskins Dec 19, 2025 2 min read Novo Nordisk has submitted a New Drug Application (NDA) to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition

Additional information Details Original published date: Media and public enquiries Media Enquiries: Health Canada 613-957-2983 [email protected] Public Enquiries: 613-957-2991 1-866-225-0709 [email protected] Get notified Receive emails about new and updated recall and safety alerts.

1 and Supplementary Tables 1 and 2)

Mazdutide appears to produce side effects that are real but manageable enough that almost nobody stops treatment